These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 15209189)

  • 1. Clinical trials referral resource. Current clinical trials of 17-AG and 17-DMAG.
    Ivy PS; Schoenfeldt M
    Oncology (Williston Park); 2004 May; 18(5):610, 615, 619-20. PubMed ID: 15209189
    [No Abstract]   [Full Text] [Related]  

  • 2. [Heat shock protein 90: novel target for cancer therapy].
    Chen Y; Ding J
    Ai Zheng; 2004 Aug; 23(8):968-74. PubMed ID: 15301726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer: the rules of attraction.
    Neckers L; Lee YS
    Nature; 2003 Sep; 425(6956):357-9. PubMed ID: 14508471
    [No Abstract]   [Full Text] [Related]  

  • 4. Heat shock protein inhibitor shows antitumor activity.
    Dunn FB
    J Natl Cancer Inst; 2002 Aug; 94(16):1194-5. PubMed ID: 12189221
    [No Abstract]   [Full Text] [Related]  

  • 5. Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator.
    Kaur G; Belotti D; Burger AM; Fisher-Nielson K; Borsotti P; Riccardi E; Thillainathan J; Hollingshead M; Sausville EA; Giavazzi R
    Clin Cancer Res; 2004 Jul; 10(14):4813-21. PubMed ID: 15269157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of the hypoxia-inducible factor system by low levels of heat shock protein 90 inhibitors.
    Ibrahim NO; Hahn T; Franke C; Stiehl DP; Wirthner R; Wenger RH; Katschinski DM
    Cancer Res; 2005 Dec; 65(23):11094-100. PubMed ID: 16322259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models.
    Smith V; Sausville EA; Camalier RF; Fiebig HH; Burger AM
    Cancer Chemother Pharmacol; 2005 Aug; 56(2):126-37. PubMed ID: 15841378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting toxic proteins for turnover.
    La Spada AR; Weydt P
    Nat Med; 2005 Oct; 11(10):1052-3. PubMed ID: 16211038
    [No Abstract]   [Full Text] [Related]  

  • 9. Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: unfolding the relationship between pharmacokinetics and pharmacodynamics.
    Workman P
    Mol Cancer Ther; 2003 Feb; 2(2):131-8. PubMed ID: 12589030
    [No Abstract]   [Full Text] [Related]  

  • 10. Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone.
    Workman P
    Cancer Lett; 2004 Apr; 206(2):149-57. PubMed ID: 15013520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hsp90 inhibitors in the clinic.
    Pacey S; Banerji U; Judson I; Workman P
    Handb Exp Pharmacol; 2006; (172):331-58. PubMed ID: 16610366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyond.
    Georgakis GV; Younes A
    Future Oncol; 2005 Apr; 1(2):273-81. PubMed ID: 16555999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent activity of a novel dimeric heat shock protein 90 inhibitor against head and neck squamous cell carcinoma in vitro and in vivo.
    Yin X; Zhang H; Burrows F; Zhang L; Shores CG
    Clin Cancer Res; 2005 May; 11(10):3889-96. PubMed ID: 15897590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dihydroquinone ansamycins: toward resolving the conflict between low in vitro affinity and high cellular potency of geldanamycin derivatives.
    Maroney AC; Marugan JJ; Mezzasalma TM; Barnakov AN; Garrabrant TA; Weaner LE; Jones WJ; Barnakova LA; Koblish HK; Todd MJ; Masucci JA; Deckman IC; Galemmo RA; Johnson DL
    Biochemistry; 2006 May; 45(17):5678-85. PubMed ID: 16634649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents.
    Chiosis G; Caldas Lopes E; Solit D
    Curr Opin Investig Drugs; 2006 Jun; 7(6):534-41. PubMed ID: 16784024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heat shock protein 90 is an essential molecular chaperone for nuclear transport of glucocorticoid receptor beta.
    Zhang X; Clark AF; Yorio T
    Invest Ophthalmol Vis Sci; 2006 Feb; 47(2):700-8. PubMed ID: 16431970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altered states: selectively drugging the Hsp90 cancer chaperone.
    Workman P
    Trends Mol Med; 2004 Feb; 10(2):47-51. PubMed ID: 15106614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heat shock protein and proteasome targeting agents.
    Takimoto CH; Diggikar S
    Hematol Oncol Clin North Am; 2002 Oct; 16(5):1269-85. PubMed ID: 12512392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Hsp90 chaperone complex as a novel target for cancer therapy.
    Goetz MP; Toft DO; Ames MM; Erlichman C
    Ann Oncol; 2003 Aug; 14(8):1169-76. PubMed ID: 12881371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
    Nguyen TK; Rahmani M; Gao N; Kramer L; Corbin AS; Druker BJ; Dent P; Grant S
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2239-47. PubMed ID: 16609040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.